Page 46 - DUOKOPT BIBLIOBOOK

DUOKOPT - bibliography book - CONFIDENTIAL - document for exclusive use by personnel of Laboratoires Théa – DO NOT DISTRIBUTE
®

Denis et al. 7

that the study required the inclusion of patients being References
able to instil themselves their treatment which obvious- 1. Tham YC, Li X, Wong TY, et al. Global prevalence
ly was not respected for a certain number. We could of glaucoma and projections of glaucoma burden
have excluded these patients from the statistical analy- through 2040: a systematic review and meta-analysis.
ses; however, for accuracy reasons, we preferred pre- Ophthalmology 2014; 121(11): 2081–2090.
senting these data. Despite this, results confirm that the 2. Barnebey HS and Robin AL. Adherence to fixed-
combination versus unfixed travoprost 0.004%/timolol
tested MDDS may be suitable for most of the patients, 0.5% for glaucoma or ocular hypertension: a randomized
providing high patient satisfaction and high treatment trial. Am J Ophthalmol 2017; 176: 61–69.
adherence. 3. Nordmann JP, Baudouin C, Bron A, et al. Xal-Ease:
Patient-reported treatment compliance with the impact of an ocular hypotensive delivery device on ease
tested MDDS was high (60.2%); 31.4% of patients of eyedrop administration, patient compliance, and sat-
having used tear substitutes decreased or even stopped isfaction. Eur J Ophthalmol 2009; 19(6): 949–956.
their use after the switch to the tested MDDS, which 4. Davis SA, Sleath B, Carpenter DM, et al. Drop instilla-
may result in an improved QoL. The patients’ capabil- tion and glaucoma. Curr Opin Ophthalmol 2018; 29(2):
171–177.
ity to correctly use their MD eye-drop delivery system 5. Weinreb RN and Khaw PT. Primary open-angle glauco-
is key to treatment adherence and ultimately to treat- ma. Lancet 2004; 363(9422): 1711–1720.
ment efficacy. Results from this study confirm that 6. Nordmann JP, Auzanneau N, Ricard S, et al. Vision
specifically adapted MDDS, such as the patented one, related quality of life and topical glaucoma treatment
increases the patient’s satisfaction of use, leads to side effects. Health Qual Life Outcomes 2003; 1: 75.
improved treatment compliance, and reduces or stops 7. Baudouin C, Renard JP, Nordmann JP, et al. Prevalence
the use of tear substitutes, thus potentially improving and risk factors for ocular surface disease among patients
efficacy. treated over the long term for glaucoma or ocular hyper-
In conclusion, the tested MDDS is highly accepted tension. Eur J Ophthalmol. Epub ahead of print 11 June
2012. DOI: 10.5301/ejo.5000181.
in the studied population and is a suitable choice for a
8. Leung EW, Medeiros FA and Weinreb RN. Prevalence
fixed-combination glaucoma therapy. Further studies
of ocular surface disease in glaucoma patients.
may be necessary to assess the easiness of use of this J Glaucoma 2008; 17(5): 350–355.
easy-to-grip delivery system in patients with greater 9. Stewart WC, Stewart JA and Nelson LA. Ocular surface
disability to instil or having severe problems in instil- disease in patients with ocular hypertension and glauco-
ling their eye drops themselves. ma. Curr Eye Res 2011; 36(5): 391–398.
10. Goldberg I, Graham SL, Crowston JG, et al. Clinical
audit examining the impact of benzalkonium chloride-
Acknowledgements
free anti-glaucoma medications on patients with symp-
The authors acknowledge the participation of the ISY study toms of ocular surface disease. Clin Exp Ophthalmol
investigators for their participation in this study and Karl 2015; 43(3): 214–220.
Patrick G€ oritz, SMWS, Scientific and Medical Writing 11. Aptel F, Labbe A, Baudouin C, et al. Glaucoma medi-
Services, France, for his medical writing assistance. cations, preservatives and the ocular surface. J Fr
Ophtalmol 2014; 37(9): 728–736.
Declaration of conflicting interests 12. Dietlein TS, Jordan JF, Luke C, et al. Self-application of
single-use eyedrop containers in an elderly population:
The author(s) declared the following potential conflicts of
comparisons with standard eyedrop bottle and with
interest with respect to the research, authorship and/or pub- younger patients. Acta Ophthalmol 2008; 86(8): 856–859.
lication of this article: The authors received honoraria from 13. Gao X, Yang Q, Huang W, et al. Evaluating eye drop
Laboratoires Th� ea for conducting this study. Moreover, P. instillation technique and its determinants in glaucoma
Denis served as a consultant for Novartis, Laboratoires Th� ea, patients. J Ophthalmol 2018; 2018: 1376020.
EyeTechCare Aerie and iStar. 14. Nordmann JP and Akesbi J. Improve adherence in glau-
coma patients: a doctor’s duty. J Fr Ophtalmol 2011;
34(6): 403–408.
Funding
15. Atey TM, Shibeshi WT, Giorgis A, et al. The impact of
The author(s) disclosed receipt of the following financial sup- adherence and instillation proficiency of topical glauco-
port for the research, authorship and/or publication of this ma medications on intraocular pressure. J Ophthalmol
article: This survey was supported by Laboratoires Th� ea, 2017; 2017: 1683430.
16. Gabisson P, Briat B, Le Foll J, et al. Handiness and
Clermont-Ferrand, France.
acceptability of the new Abak bottle in chronically
treated patients. Ann Pharm Fr 2011; 69(1): 22–29.
Supplemental material 17. Recommendations for professional standards good epi-
Supplemental material for this article is available online. demiological practices (version France 2007).

46